Zobrazeno 1 - 10 of 204 pro vyhledávání: '"B. van Hout"'
1
Akademický článek
Deep Vein Thrombosis in Europe—Health-Related Quality of Life and Mortality
Autor: M. Monreal MD, PhD, G. Agnelli PROF, L. H. Chuang PhD, A. T. Cohen MBBS, MSc, MD, FRACP, FESC, P. D. Gumbs PhD, R. Bauersachs MD, P. Mismetti MD, A. K. Gitt, S. Kroep PhD, S. N. Willich MD, B. Van Hout PROF
Publikováno v: Clinical and Applied Thrombosis/Hemostasis, Vol 25 (2019)
Objectives: Deep vein thrombosis (DVT) is a major health-care burden in Europe, but exact estimates are lacking. This study reports results from the PREFER venous thromboembolism (VTE) study concerning health-related quality of life (HrQoL) and morta
Externí odkaz: https://doaj.org/article/52dfb832549d49b1b7c80e9e8c76d980
Zobrazit plný text záznamu
2
Akademický článek
Protocol and preregistration for the CODEC project: measuring, modelling and mechanistically understanding the nature of cognitive variability in early childhood
Autor: Ilse E. J. I. Coolen, Jordy van Langen, Sophie Hofman, Fréderique E. van Aagten, Jessica V. Schaaf, Lea Michel, Michael Aristodemou, Nicholas Judd, Aran T. B. van Hout, Emma Meeussen, Rogier A. Kievit
Publikováno v: BMC Psychology, Vol 12, Iss 1, Pp 1-26 (2024)
Abstract Background Children’s cognitive performance fluctuates across multiple timescales. However, fluctuations have often been neglected in favour of research into average cognitive performance, limiting the unique insights into cognitive abilit
Externí odkaz: https://doaj.org/article/7afd7b5ac5d349e6902533ad8b5a04ef
Zobrazit plný text záznamu
3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
7
Does Evolocumab use in Europe match 2019 ESC/EAS lipid guidelines? Results from the HEYMANS study
Autor: Eric Bruckert, B. van Hout, I Bridges, Kausik K. Ray, M. Feudjo Tepie, M Sibartie
Publikováno v: European Heart Journal. 41
Background 2019 ESC/EAS dyslipidaemia guidelines recommend a 50% lowering in untreated LDL-C and use of PCSK9 inhibitors (PCSK9i) for patients at very-high cardiovascular (CV) risk when LDL-C target goals of Purpose This observational study describes
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b0723ac69446c1d9cf4ba5dd82ddb8dc
https://doi.org/10.1093/ehjci/ehaa946.3013
Zobrazit plný text záznamu
8
Additive predictive power of the CHA2DS2-VASc and HAS-BLED scores for mortality in patients with atrial fibrillation
Autor: Fabrizio Ricci, S Kroep, P Kirchhof, Giuseppe Patti, B. van Hout, R. De Caterina, L.C Chuang, Doralisa Morrone, Giulia Renda
Publikováno v: European Heart Journal. 41
Background and objectives In atrial fibrillation (AF), assessment of thromboembolic and bleeding risks are recommended to prescribe anticoagulation for stroke prevention. However, AF also increases mortality, and predictors of death are less characte
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d32c0da4a3af3b736811117c90828f87
https://doi.org/10.1093/ehjci/ehaa946.0648
Zobrazit plný text záznamu
9
What potential risk reduction could be achieved with evolocumab treatment? A simulation based on observational data from a cohort of users in 10 European countries
Autor: Eric Bruckert, Kausik K. Ray, B. van Hout, G. Villa, M Sibartie, I Bridges
Publikováno v: European Heart Journal. 41
Background/Introduction The FOURIER trial enrolled very high-risk patients with a mean LDL-C of 2.5 mmol/L, and demonstrated that evolocumab reduced major cardiovascular events by 1.5% in absolute terms over 2.2 years. Further research may be conduct
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::703b32b497c55b0fee0b059b74cedd1c
https://doi.org/10.1093/ehjci/ehaa946.3004
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje